Neumayer Matthew Paul

Avg. Two Year Performance

No purchase track record

24% Avg. Sale Return

11% Compound

	1 Mo	3 Mo	6 Mo	1 Yr	2 Yr
Average Purchase Return	--	--	--	--	--
Purchase Success Rate	--	--	--	--	--
Average Sale Return	13%	21%	18%	17%	24%
Sale Success Rate	2 of 2	2 of 2	2 of 2	1 of 2	2 of 2

Osiris Therapeutics, Inc.

Drugs » Biotechnology

Principal Accounting Officer:

Holdings: 0 shares

Sentiment

Avg. Two Year Performance

No purchase track record

No sale track record

Last Three Months:

0 Net Amount

Buy:	0	--
Sell:	0	--